Bivalent inactivated avian influenza vaccine developed in China

Introduction: People's network, Beijing, November 9, reporter Jiang Jianke reported that the first batch of national new drug, avian influenza bivalent inactivated vaccine, jointly developed and produced by the Institute of animal quarantine of the Ministry of agriculture and Qingdao Yibang Bioengineering Co., Ltd., was officially put on the market after being approved and issued by China veterinary drug administration The vaccine can prevent H5 subtype and H9 subtype avian influenza at the same time, and will play an important role in the prevention and control of avian influenza in China At present, there are 15 h subtypes of influenza virus, which are mainly H5 subtype and H9 subtype Among them, H5 subtype avian influenza virus can cause 100% morbidity and death of susceptible birds, and individual strains can also cause morbidity and death of susceptible human body, which is listed as a class a severe infectious disease by the international organization for animal health; although H9 subtype avian influenza virus belongs to mild influenza virus, it can also cause 100% morbidity and 10-50% mortality of susceptible young birds, and the egg production of laying birds is seriously reduced or even terminated The newly developed bivalent inactivated vaccine for avian influenza can prevent these two diseases at the same time The immune effect is the same as that of the two single vaccines After 14 days of immunization, it can produce strong protective power, and the production cost is equivalent to 60% of the two single vaccines Therefore, the research results not only fill the gaps of domestic and foreign products, but also greatly facilitate the production of poultry industry and save the cost of epidemic prevention Experts believe that it is a critical period to prevent avian influenza, and the product will be put into production in due time, which will provide strong technical support and material guarantee for the prevention and control of avian influenza in China this year.